<DOC>
	<DOCNO>NCT02923349</DOCNO>
	<brief_summary>The purpose study determine safety tolerability ass preliminary efficacy INCAGN01949 subject advanced metastatic solid tumor .</brief_summary>
	<brief_title>A Phase 1/2 , Open-Label , Dose-Escalation , Safety Study INCAGN01949 Subjects With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Locally advanced metastatic disease ; locally advanced disease must amenable resection curative intent . Subjects disease progression treatment available therapy know confer clinical benefit , intolerant treatment , refuse standard treatment . There limit number prior treatment regimen . Part 1 : Subjects advance metastatic solid tumor . Part 2 : Subjects advance metastatic adenocarcinoma endometrium , ovarian cancer , renal cell carcinoma , melanoma , nonsmall cell lung cancer . Presence measureable disease base RECIST v1.1 . Eastern Cooperative Oncology Group performance status 0 1 . Laboratory medical history parameter within protocoldefined range . Receipt anticancer medication investigational drug within protocoldefined interval first administration study drug . Has recover â‰¤ Grade 1 toxic effect prior therapy ( include prior immunotherapy ) and/or complication prior surgical intervention start therapy . Receipt live vaccine within 30 day plan start study drug . Active autoimmune disease require systemic treatment past .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>adenocarcinoma endometrium</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>melanoma</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>OX40</keyword>
	<keyword>immunoglobulin G monoclonal antibody</keyword>
</DOC>